Using QPOP to Predict Treatment for Sarcomas and Melanomas
About this study
This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo. Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.
- Condition
- Sarcoma, Melanoma
- Sponsor
- National Cancer Centre, Singapore
Who can join
- Age
- 21 to 99 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 21 years
- Maximum age: 99 years
- Study condition: Sarcoma, Melanoma
- Diagnosis of sarcoma or melanoma
- At least 1 tumour lesion amenable to fresh biopsy or resection
- Signed informed consent from patient or legal representative
- Able to comply with study-related procedures
Exclusion 1
- There are no specific exclusion criteria if patients meet the inclusion criteria
Where
1 site, 1 recruiting
National Cancer Centre Singapore
Singapore, Singapore
Contact
-
Valerie Shiwen Yang, BSc, MB BChir, PhD
+65 6436 8088 valerie.yang.s.w@singhealth.com.sg
Potential match only. Final eligibility is determined by the study team.